Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

peginesatide

Known as: Erythropoiesis-Stimulating Agent (ESA) 
A synthetic, non-recombinant, pegylated, peptidic erythropoiesis stimulating agent. Synthetic peptide-based erythropoiesis stimulating agent binds to… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
The UK-based National Institute for Health and Care Excellence (NICE) has updated its guidance on iron deficiency and anemia… Expand
2015
2015
BACKGROUND In haemodialysis (HD) patients, anaemia is associated with reduced survival. Despite treatment with erythropoiesis… Expand
  • table 1
Highly Cited
2013
Highly Cited
2013
BACKGROUND Peginesatide is a peptide-based erythropoiesis-stimulating agent (ESA) that may have therapeutic potential for anemia… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 2
Review
2013
Review
2013
The KDIGO (Kidney Disease: Improving Global Outcomes) 2012 clinical practice guideline for anemia management in patients with… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Highly Cited
2013
Highly Cited
2013
BACKGROUND Peginesatide, a synthetic peptide-based erythropoiesis-stimulating agent (ESA), is a potential therapy for anemia in… Expand
  • table 1
  • figure 2
  • table 2
  • figure 3
Review
2012
Review
2012
BACKGROUND The anaemia seen in chronic kidney disease (CKD) may be exacerbated by iron deficiency. Iron can be provided through… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
  • figure 6
Highly Cited
2011
Highly Cited
2011
Background. Intravenous (i.v.) iron sucrose similar (ISS) preparations are available but clinical comparisons with the originator… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2011
Highly Cited
2011
BACKGROUND Shortening of red blood cell (RBC) survival contributes to the anemia of chronic kidney disease. The toxic uremic… Expand
Highly Cited
2010
Highly Cited
2010
Randomized trials have endeavored to show that using ESAs to raise hemoglobin concentrations to higher targets improves clinical… Expand
Highly Cited
2008
Highly Cited
2008
Patients with myelodysplastic syndromes (MDS) often develop anaemia resulting in frequent transfusions and fatigue. Darbepoetin… Expand